David A Kalmbach1, Philip Cheng1, Thomas Roth1, Chaewon Sagong1, Christopher L Drake2. 1. Thomas Roth Sleep Disorders & Research Center, Henry Ford Health System, Detroit, MI, 48202, USA. 2. Thomas Roth Sleep Disorders & Research Center, Henry Ford Health System, Detroit, MI, 48202, USA. Electronic address: cdrake1@hfhs.org.
Abstract
STUDY OBJECTIVES: To determine whether insomnia patients with objective sleep disturbance are less responsive to cognitive and behavioral treatments than those without objective sleep disturbance, characterize effects of insomnia therapy on objective sleep, and determine whether reductions in nocturnal cognitive arousal correspond to changes in objective sleep. METHODS: Secondary analysis of a single-site, randomized controlled trial. 113 postmenopausal women (56.40 ± 5.34 years) with menopause-related insomnia disorder were randomized to three treatment conditions: cognitive-behavioral therapy for insomnia (CBTI), sleep restriction therapy (SRT), or sleep education control. Primary outcomes were the Insomnia Severity Index (ISI) and polysomnography (PSG) sleep parameters and were collected at pretreatment, posttreatment, and six-month follow-up. RESULTS: Patients with lower pretreatment PSG sleep efficiency had lower rates of insomnia remission after active treatment relative to those with higher sleep efficiency (37.8% vs 61.8%). Neither CBTI and SRT produced clinically meaningful effects on PSG sleep. Exploratory analyses revealed that reductions in nocturnal cognitive arousal were associated with decreases in PSG sleep latency, but not wake after sleep onset. CONCLUSIONS: Our findings support an emerging literature suggesting that insomnia patients with objective sleep disturbance may have blunted response to insomnia therapy. Research is needed to enhance treatments to better improve insomnia in patients with objective sleep disturbance. A lack of observed CBTI and SRT effects on PSG sleep suggests that these therapies may be presently ill-designed to improve objective sleep. Nocturnal cognitive arousal may represent an entry point to improve objective sleep latency in insomnia. NAME: Behavioral Treatment of Menopausal Insomnia: Sleep and Daytime Outcomes. URL: clinicaltrials.gov. Registration: NCT01933295.
RCT Entities:
STUDY OBJECTIVES: To determine whether insomniapatients with objective sleep disturbance are less responsive to cognitive and behavioral treatments than those without objective sleep disturbance, characterize effects of insomnia therapy on objective sleep, and determine whether reductions in nocturnal cognitive arousal correspond to changes in objective sleep. METHODS: Secondary analysis of a single-site, randomized controlled trial. 113 postmenopausal women (56.40 ± 5.34 years) with menopause-related insomnia disorder were randomized to three treatment conditions: cognitive-behavioral therapy for insomnia (CBTI), sleep restriction therapy (SRT), or sleep education control. Primary outcomes were the Insomnia Severity Index (ISI) and polysomnography (PSG) sleep parameters and were collected at pretreatment, posttreatment, and six-month follow-up. RESULTS:Patients with lower pretreatment PSG sleep efficiency had lower rates of insomnia remission after active treatment relative to those with higher sleep efficiency (37.8% vs 61.8%). Neither CBTI and SRT produced clinically meaningful effects on PSG sleep. Exploratory analyses revealed that reductions in nocturnal cognitive arousal were associated with decreases in PSG sleep latency, but not wake after sleep onset. CONCLUSIONS: Our findings support an emerging literature suggesting that insomniapatients with objective sleep disturbance may have blunted response to insomnia therapy. Research is needed to enhance treatments to better improve insomnia in patients with objective sleep disturbance. A lack of observed CBTI and SRT effects on PSG sleep suggests that these therapies may be presently ill-designed to improve objective sleep. Nocturnal cognitive arousal may represent an entry point to improve objective sleep latency in insomnia. NAME: Behavioral Treatment of Menopausal Insomnia: Sleep and Daytime Outcomes. URL: clinicaltrials.gov. Registration: NCT01933295.
Authors: Jeanne E Maglione; Sonia Ancoli-Israel; Katherine W Peters; Misti L Paudel; Kristine Yaffe; Kristine E Ensrud; Katie L Stone Journal: Sleep Date: 2014-07-01 Impact factor: 5.849
Authors: Christopher B Miller; Colin A Espie; Delwyn J Bartlett; Nathaniel S Marshall; Christopher J Gordon; Ronald R Grunstein Journal: Sci Rep Date: 2018-04-27 Impact factor: 4.379
Authors: Sheera F Lerman; Chung Jung Mun; Carly A Hunt; Shriya Kunatharaju; Luis F Buenaver; Patrick H Finan; Claudia M Campbell; Jane Phillips; Julio Fernandez-Mendoza; Jennifer A Haythornthwaite; Michael T Smith Journal: Sleep Med Date: 2022-01-08 Impact factor: 3.492
Authors: Jack D Edinger; Simon Beaulieu-Bonneau; Hans Ivers; Bernard Guay; Lynda Bélanger; Bryan Simmons; Charles M Morin Journal: Sleep Date: 2022-01-11 Impact factor: 5.849
Authors: Alexander Sweetman; Bastien Lechat; Peter G Catcheside; Simon Smith; Nick A Antic; Amanda O'Grady; Nicola Dunn; R Doug McEvoy; Leon Lack Journal: Front Psychol Date: 2021-05-04
Authors: Alexandria Muench; Ivan Vargas; Michael A Grandner; Jason G Ellis; Donn Posner; Célyne H Bastien; Sean Pa Drummond; Michael L Perlis Journal: Fac Rev Date: 2022-02-01